Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Weekly doses of an antisense inhibitor of apolipoprotein C-III (APOC3) in persons with severe or uncontrolled hypertriglyceridemia resulted in a reduction in APOC3 and triglyceride levels at the end of 13 weeks.
Elevated triglyceride levels are associated with several pathologic conditions, including insulin resistance, the metabolic syndrome, d...
Alternative Titles
Full title
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1700684753
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1700684753
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1400283
